Pasadena, California 91105

  • Alcoholic Fatty Liver Disease

Purpose:

Lovaza is the only fish oil supplement approved by the FDA. It is available by prescription for the treatment of hypertriglyceridemia (> 500 mg/dl). The primary mechanism appears to be a reduction in hepatic production of triglycerides. Also decreases the hepatic production of very low density lipoprotein (VLDL). There also may be antioxidant properties as well. The thought behind using Lovaza as a treatment for non-alcoholic fatty liver disease (NAFLD) is two fold. It would help in the decrease production of triglycerides by the liver and have antioxidant properties decreasing the production of free radicals in the liver. In doing so, steatohepatitis, fibrosis, and perhaps cirrhosis and liver cancer would be prevented.


Criteria:

Inclusion Criteria: - Over the age of 18 - Abnormal liver enzymes >40 IU/L. Definition of normal is ALT 19 for a woman and 30 for a man. - Patients must meet ATP III criteria for metabolic syndrome: Central obesity as measured by waist circumference. Men - greater than or equal to 40 inches. Women - greater than or equal to 35 inches. - Blood HDL cholesterol. Men - less than 40 mg/dL. Women - less than 50 mg /dL. - Blood pressure greater than or equal to 130/85. - Fasting glucose greater than or equal to 100 mg/dL but less than 126mg/dL on 2 separate occasions. - Fasting blood triglycerides greater than or equal to 150 mg/dL. - Hepatitis B and C negative - Autoimmune Hepatitis, Wilson's Disease, Hemochromatosis negative, etc. - NASH or NAFLD on biopsy of any degree: Exclusion Criteria: - Below the age of 18. - Other Causes of Liver inflammation. - Daily alcohol consumption in excess of 20 grams / day for men and 10 grams / day for women. If participant unable to quantify his/her alcohol intake, they should be excluded. - Taking a prescribed medication know to cause fatty liver disease 6 months prior to enrollment. Also, subjects with secondary causes of fatty liver disease (ie. Gastric bypass) should be excluded from the study. - Cirrhosis. - Subjects on oral insulin-sensitizing agents and other drugs currently being used in the treatment of NAFLD. Such agents include fibrates, Vitamin E, S-adenosyl-methionine, betaine, N-acetylcysteine, and milk thistle extracts. - Diabetes (fasting sugar above 126mg/dl). - Pregnancy or lactation. Women of child bearing potential must have a negative serum pregnancy test at screening, a negative urine pregnancy test prior to treatment and be practicing an acceptable form of barrier contraception for the duration of the study. - Any serious or chronic disease that in the opinion of the Principal Investigator (PI), may affect the assessment of safety or efficacy parameters. This includes but is not limited to, patients with malignancy, other than Basal Cell Carcinomas. - Patients who, in the opinion of the site PI, are not suitable candidates for enrollment or would not comply with the requirements of the study. - Patients who have had a liver transplant. - Any allergy to fish.


NCT ID:

NCT00941642


Primary Contact:

Principal Investigator
Edward A Mena, MD
Huntington Medical Research Institutes - Liver Center

Roberta A Fitzgerald, RN
Phone: 626.397.5825
Email: robertaf@hmri.org


Backup Contact:

N/A


Location Contact:

Pasadena, California 91105
United States

Roberta A Fitzgerald, RN
Phone: 626-397-5825
Email: robertaf@hmri.org

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: September 27, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.